Co-Diagnostics (CODX) JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics ("IVD").

The Saragene test kits approved by the CDSCO use the Company's patented CoPrimer™ technology for the qualitative detection of these mosquito-borne viruses.

According to the World Health Organization, the global incidence of dengue has grown dramatically in recent decades to become a leading cause of death in some Asian and Latin American countries, with 70% of the burden in Asia despite a risk of infection existing in 129 countries. About half of the world's population is now at risk, leading to an estimated 100-400 million infections each year.

While less lethal than dengue, chikungunya has been considered by the WHO to have serious epidemic potential, due to its potential to cause considerable disability in a proportion of the affected population and ultimately substantial socioeconomic impact in those areas.

CoSara Director Mohal Sarabhai remarked, "India Today recently reported that dengue and chikungunya cases are up 110% since January in Gujarat, where CoSara is headquartered. We are pleased to be able to add two more products to our menu of diagnostics that can all be manufactured in India in agreement with the 'Make in India' initiative, as well as exported to help serve the needs of this region of the world which is highly burdened by the effects of these two diseases."

Dwight Egan, CEO of Co-Diagnostics, commented, "The first step in effective treatment of infectious diseases is an accurate diagnosis. Our highly-specific CoPrimer technology is ideally suited to distinguish between similar diseases like dengue and chikungunya, and we believe that these tests have the potential to improve the lives of infected patients through more accessible and accurate diagnoses leading to better treatment."

CoSara has previously received CDSCO clearance for RT-PCR tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C, human papillomavirus (HPV), and two COVID-19 assays, all to be manufactured and sold as IVDs in the Indian market.

You May Also Be Interested In

• Ocugen (OCGN) Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
• Takeda (TAK) U.S. FDA Approves Subcutaneous Administration of ENTYVIO
• Alvotech (ALVO) signs U.S. agreement to expand access for adalimumab